{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Connect Biopharma Holdings Limited"},"Symbol":{"label":"Symbol","value":"CNTB"},"Address":{"label":"Address","value":"6 BEIJING WEST ROAD,EAST R&D BUILDING, 3RD FLOOR SUITE 350, TAICANG, 215400, China"},"Phone":{"label":"Phone","value":"+86 51253577866"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233."},"CompanyUrl":{"label":"Company Url","value":"https://www.connectbiopharm.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Barry D. Quart","title":"Chief Executive Officer & Director"},{"name":"Raul Collazo","title":"Vice President, Global Head-Medical Affairs"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}